Grant: CIHR Fellowship
Direct Payment
$150,000.00
Collagen VI related myopathies: Defining, exploring and advancing targets for molecular treatments
FY 2010-11
Summary
Congenital muscular dystrophies (CMDs) are disorders of muscle that present with significant weakness at birth or in early infancy. CMDs as a group are an important yet under-recognized cause of early childhood neuromuscular morbidity. There are currently no causally effective treatments for these disorders. The most common subgroup of CMDs comprise the disorders caused by mutations in the three genes coding for collagen type VI, one of the two major microfibrillar components of the extracellular matrix surrounding the muscle tissue. Dominant mutations (meaning that one affected gene copy is able to cause disease) are the predominant mutation mechanism in collagen VI related muscle disease and the severity of these dominant mutations results from their ability to negatively interfere with any normal collagen VI formed (referred to as a dominant negative effect). This situation poses formidable challenges to the development of molecular treatments, as simple gene replacement approaches will not work because of the continued presence of the offending mutant transcript. With this project we will develop two basic strategies to define treatment options for this difficult situation. One approach is to carefully define why the lack of normal collagen VI is detrimental to the muscle cells in an effort to find molecular targets at which drug therapies could be directed in order to increase the resistance of muscle cells to the collagen VI deficiency. The other more causative approach to the dominant negative mutations in collagen VI that we will pursue is to take down the mutant gene product that is interfering with normal collagen VI production, using a molecular strategy called RNA interference technology. This strategy has the potential of substantially improving the amount of functional collagen VI available. Such targets could eventually also be useful for other muscle disorders in which similar mechanisms play a role.
Department
Program
CIHR Fellowship
Recipient
Location
Maryland, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
227347
Name
Bolduc Véronique
Region
Maryland
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Collagen VI related myopathies: Defining, exploring and advancing targets for molecular treatments
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cell Biology; Congenital Muscular Dystrophies; Genetics; Molecular Treatment
Abstract
Congenital muscular dystrophies (CMDs) are disorders of muscle that present with significant weakness at birth or in early infancy. CMDs as a group are an important yet under-recognized cause of early childhood neuromuscular morbidity. There are currently no causally effective treatments for these disorders. The most common subgroup of CMDs comprise the disorders caused by mutations in the three genes coding for collagen type VI, one of the two major microfibrillar components of the extracellular matrix surrounding the muscle tissue. Dominant mutations (meaning that one affected gene copy is able to cause disease) are the predominant mutation mechanism in collagen VI related muscle disease and the severity of these dominant mutations results from their ability to negatively interfere with any normal collagen VI formed (referred to as a dominant negative effect). This situation poses formidable challenges to the development of molecular treatments, as simple gene replacement approaches will not work because of the continued presence of the offending mutant transcript. With this project we will develop two basic strategies to define treatment options for this difficult situation. One approach is to carefully define why the lack of normal collagen VI is detrimental to the muscle cells in an effort to find molecular targets at which drug therapies could be directed in order to increase the resistance of muscle cells to the collagen VI deficiency. The other more causative approach to the dominant negative mutations in collagen VI that we will pursue is to take down the mutant gene product that is interfering with normal collagen VI production, using a molecular strategy called RNA interference technology. This strategy has the potential of substantially improving the amount of functional collagen VI available. Such targets could eventually also be useful for other muscle disorders in which similar mechanisms play a role.
Competitiondate
201102
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bolduc, Véronique
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~